PMID- 24569364
OWN - NLM
STAT- MEDLINE
DCOM- 20140506
LR  - 20211021
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 124
IP  - 3
DP  - 2014 Mar
TI  - NRF2 mitigates radiation-induced hematopoietic death.
PG  - 960-1
LID - 74143 [pii]
LID - 10.1172/JCI74143 [doi]
AB  - Fractionated, high-dose total body irradiation (TBI) is used therapeutically to 
      myeloablate and immune suppress patients undergoing hematopoietic stem cell (HSC) 
      transplantation. Acute exposure to ionizing radiation can have fatal effects on 
      the hematopoietic and immune systems. Currently, therapies aimed at ameliorating 
      ionizing radiation-associated toxicities are limited. In the February 2014 issue 
      of the JCI, Kim and colleagues demonstrated that induction of nuclear factor 
      erythroid 2-related factor 2 (NRF2) enhances HSC regeneration and increases 
      survival following ionizing radiation exposure in mice. The results of this study 
      suggest that NRF2 is a novel potential target for the development of therapeutics 
      aimed at mitigating the toxicities of ionizing radiation exposure.
FAU - Chute, John P
AU  - Chute JP
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20140224
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Receptors, Notch)
SB  - IM
CON - J Clin Invest. 2014 Feb;124(2):730-41. PMID: 24463449
MH  - Animals
MH  - Hematopoiesis/*radiation effects
MH  - Hematopoietic Stem Cells/*radiation effects
MH  - NF-E2-Related Factor 2/*metabolism
MH  - Receptors, Notch/*metabolism
PMC - PMC3938265
EDAT- 2014/02/27 06:00
MHDA- 2014/05/07 06:00
PMCR- 2015/01/01
CRDT- 2014/02/27 06:00
PHST- 2014/02/27 06:00 [entrez]
PHST- 2014/02/27 06:00 [pubmed]
PHST- 2014/05/07 06:00 [medline]
PHST- 2015/01/01 00:00 [pmc-release]
AID - 74143 [pii]
AID - 10.1172/JCI74143 [doi]
PST - ppublish
SO  - J Clin Invest. 2014 Mar;124(3):960-1. doi: 10.1172/JCI74143. Epub 2014 Feb 24.